Fig. 2.

Matching-adjusted odds ratio comparison of bimekizumab vs secukinumab (150 mg and 300 mg) at week 52 (NRI). a BKZ 160 mg Q4W vs SEC 150 mg Q4W in patients with PsA who were bDMARD-naïve, b BKZ 160 mg Q4W vs SEC 300 mg Q4W in patients with PsA who were bDMARD-naïve, c BKZ 160 mg Q4W vs SEC 150 mg Q4W in patients with PsA who were TNFi-IR, d BKZ 160 mg Q4W vs SEC 300 mg Q4W in patients with PsA who were TNFi-IR. *Indicates statistical significance. Figure shows a logarithmic scale. ACR American College of Rheumatology, ACR20/50/70 at least a 20/50/70% improvement according to the ACR response criteria, bDMARD biologic disease-modifying anti-rheumatic drugs, BKZ bimekizumab, CI confidence interval, ESS effective sample size, MDA minimal disease activity, NRI non-responder imputation, OR odds ratio, PsA psoriatic arthritis, pts patients, Q4W every 4 weeks, SEC secukinumab, TNFi-IR tumor necrosis factor inhibitor-inadequate response or intolerant